# CytoReason

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytoreason

- Industry: Healthcare IT
- Headquarters: Tel Aviv, Israel
- Website: www.cytoreason.com
- Total disclosed funding: $80M
- Latest round: Series B (Jul 17, 2024)
- Investors on record: 4

## About

CytoReason Ltd., based in Israel, specializes in AI-driven disease modeling solutions that assist in understanding human diseases, treatments, and patient demographics for the healthcare sector.Founded in 2016 in Tel Aviv, Israel, CytoReason Ltd. develops advanced disease modeling platforms. Led by CEO David Harel, the company has successfully raised USD 80.00 mn in Series B funding, attracting notable investors such as NVIDIA Corporation and Thermo Fisher Scientific. To date, CytoReason has completed 3 deals.CytoReason specializes in advanced AI-driven disease models that facilitate the modeling and comparison of human diseases, treatments, and patient demographics. Their core product offering is a comprehensive platform that integrates live human data to provide insights into disease mechanisms and drug efficacy. This technology enables pharmaceutical companies, biotechs, and research institutions to prioritize drug development programs, optimize treatment strategies, and enhance patient outcomes through data-driven decision-making. CytoReason's client base includes notable organizations in the healthcare sector, including partnerships with major pharmaceutical companies. Their products are utilized primarily in North America and Europe, serving markets that are focused on immunology, inflammation, and other complex disease areas.CytoReason generates revenue primarily through collaborations and licensing agreements with pharmaceutical and biotechnology firms, engaging in B2B transactions where clients subscribe to access its disease modeling platform. Collaborations may involve licensing proprietary disease models tailored for specific therapeutic areas, such as inflammatory bowel disease (IBD), which can be part of multi-million USD agreements. These partnerships often include ongoing support and updates to the models to align with the latest clinical data, fostering continuous engagement with clients. This transactional structure enhances CytoReason's revenue stream and solidifies its role as a key technology partner in the biomedical research landscape.CytoReason plans to utilize its recent funding to continue developing innovative disease models and expand its offerings. The company is targeting entry into additional markets in Asia and South America, aiming for significant presence by 2025. The funding raised will support these strategic initiatives, ensuring that CytoReason remains at the forefront of biomedical research technology.

## Funding rounds

- Series B, Jul 17, 2024, $80M — Pfizer Pension Trust, NVIDIA Corporation, OurCrowd, Thermo Fisher Scientific Corporate Development/Ventures

## Investors

- Pfizer Pension Trust — Series B
- NVIDIA Corporation — Series B
- OurCrowd (https://capitalatlas.ai/funds/ourcrowd) — Series B
- Thermo Fisher Scientific Corporate Development/Ventures — Series B